Best of ASCO 2009
胡夕春
复旦大学附属肿瘤医院
Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial.
编辑: ludongcn 作者:丁香园通讯员